Atopic Dermatitis with focus on Sub-Saharan Africa: Training for national and district-level health workers To access the course, you can either use this link https://whoacademy.org/ or type the course title in the search space. To enroll in the course, you will need to create an account if you have not already done so. Atopic dermatitis is […]
Read More
Research Trends in Epidemiology and Genetics of Atopic Dermatitis The Rise of Atopic Dermatitis in the Elderly Population Until the early 2000s, atopic dermatitis (AD) was primarily considered a pediatric condition. In older adults, a diagnosis of AD was often dismissed due to its perceived low incidence and frequently misclassified as senile pruritus, pre-bullous pemphigoid, […]
Read More
How COVID Quarantine May Have Fueled Infantile AD + Hidden Signs of Pruritus in Infants with AD + From Modeling Temperature Fluctuations to Blocking TRPV1: Restoring the Skin Barrier and Treating Pruritus + Can Early Short-Term Moisturizer Use Rewrite an Infant’s Microbiome and Prevent Atopic Dermatitis? + Serine Sensing System for tracking moisturizer treatment of a patient with AD
Read More
#event #free #online The recording is now available! Imagine a group of people, bound in a dark cave, seeing only flickering shadows on the wall. These shadows are their reality—until one escapes and discovers the truth beyond the cave. This is Plato’s Allegory of the Cave—and it’s also the modern reality of atopic dermatitis misinformation […]
Read More
April 16–18, Cotonou, Benin The « 3rd Journées Béninoises de Dermato-Vénérologie », held from April 16–18 in Cotonou under the auspices of the Ministry of Health of the Republic of Benin, was more than just a national dermatology conference. In a country with only about two dozen dermatologists serving a population of 13 million, Benin […]
Read More
The WHO EML Secretariat invites interested stakeholders to submit comments on the A-30 application. The deadline for submission of comments is Friday 18 April 2025, 18h00 CEST (Zürich time). ➜ Comments should be provided by via email to emlsecretariat@who.int in PDF format and must clearly reference the application A-30. ➜ Comments received will be published on […]
Read More
Highlights from the WHO Global Meeting on skin NTDs The much-anticipated Second WHO Global Meeting on Skin NTDs, held from March 24-26, 2025, at WHO headquarters in Geneva, provided a crucial platform to assess the progress made since the launch of the Strategic Framework for Skin NTDs in June 2022. This framework sets ambitious goals […]
Read MoreCrusted Scabies and Dupilumab: A Case from Brazil + Seasonal Severity of AD by Birth Season: What’s the Culprit? + Primary Atopic Disorders (PADs): When Should This Be Considered? + Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) Lower the Risk of New-Onset Atopic Dermatitis in Diabetic Patients: Another Clue in the Salt Debate? + Targeting the OX40-OX40L Pathway: A New Era in AD Management?
Read More
Towards a Better Definition of Therapeutic Concepts in Atopic Dermatitis: Learning from Rheumatoid Arthritis Dear Colleagues, Dear Friends, Since the 1980s, rheumatoid arthritis (RA) has served as a model for therapeutic strategies in chronic inflammatory diseases. RA activity is assessed using multiple measures, including swollen joint counts, inflammatory markers, and radiographic signs of joint damage. […]
Read More
Defining a good indication of nemoluzimab based on clinical criteria➜ DOI: 10.1111/1346-8138.17626Nemolizumab is an effective treatment for pruritus in atopic dermatitis, but it has a relatively high incidence of cutaneous adverse events (cAEs). To optimize the use of nemolizumab, Japanese researchers investigated the relationship between baseline severity in specific body areas and the frequency of cAEs. [...] Read More